debrisoquin has been researched along with Disease Models, Animal in 4 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, RR | 1 |
| Zheng, YW | 1 |
| Li, B | 1 |
| Tsuchida, T | 1 |
| Ueno, Y | 1 |
| Nie, YZ | 1 |
| Taniguchi, H | 1 |
| Schlaich, MP | 1 |
| Socratous, F | 1 |
| Hennebry, S | 1 |
| Eikelis, N | 1 |
| Lambert, EA | 1 |
| Straznicky, N | 1 |
| Esler, MD | 1 |
| Lambert, GW | 1 |
| Mantle, PG | 1 |
| Amirtharajah, M | 1 |
| Klippel, S | 1 |
| Miljkovic, A | 1 |
| Naik, JT | 1 |
| Nestler, S | 1 |
| Ohta, S | 1 |
| Tachikawa, O | 1 |
| Makino, Y | 1 |
| Tasaki, Y | 1 |
| Hirobe, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Renal SympAthetic DenerVation on Chronic HypErtension[NCT01628198] | 38 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to recommendation by the study's DSMB due to insufficient data to determine efficacy.) | |||
| Renal Sympathetic Denervation for the Management of Chronic Hypertension[NCT01628172] | 96 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change in diastolic blood pressure as measured by 24 hour ambulatory monitoring at 6 months as compared to from baseline. (NCT01628198)
Timeframe: baseline and 6 months
| Intervention | mmHg mean change (Mean) |
|---|---|
| Renal Denervation Group | -5.5 |
The change in systolic blood pressure as measured by 24 hour ambulatory monitoring at 6 months as compared to from baseline. (NCT01628198)
Timeframe: baseline and 6 months
| Intervention | mmHg (Mean) |
|---|---|
| Renal Denervation Group | -10.2 |
The total number of anti-hypertensive medications at baseline, 6 months, and 12 months (NCT01628198)
Timeframe: Baseline, 6 months, 12 months
| Intervention | medications (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Renal Denervation Group | 5.37 | 4.79 | 4.64 |
A blood urea nitrogen (BUN) test measures the amount of nitrogen in blood that comes from the waste product urea. Urea is made when protein is broken down in the body. Urea is made in the liver and passed out in the urine. (NCT01628198)
Timeframe: baseline, 6 months, 12 months
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Renal Denervation Group | 20.82 | 22.15 | 23.11 |
Creatinine measures the level of the waste product in the body. The amount of creatinine in the blood depends partly on the amount of muscle tissue you have. Men generally have higher creatinine levels than women.Normal levels of creatinine in the blood are approximately 0.6 to 1.2 milligrams (mg) per deciliter (dL) in adult males and 0.5 to 1.1 milligrams per deciliter in adult females. High levels of creatinine indicates kidney impairment. (NCT01628198)
Timeframe: baseline, 6 months, 12 months
| Intervention | mg/dl (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Renal Denervation Group | 1.6 | 1.68 | 2.03 |
Different time points office diastolic blood pressure measurements (NCT01628198)
Timeframe: baseline, 6 month, 12 months
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Renal Denervation Group | 87.06 | 86.93 | 87.75 |
Different time points office systolic blood pressure measurements (NCT01628198)
Timeframe: baseline, 6 month, 12 months
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Renal Denervation Group | 156.86 | 151.19 | 158.45 |
Renal artery blood flow as measured by Renal Aortic Ratio (RAR) = Peak systolic Velocity renal artery / Peak Systolic Velocity Aorta. A >60% stenosis is reported when there is a >3.5:1 Renal to Aortic Ratio. (NCT01628198)
Timeframe: Baseline and 12 months
| Intervention | ratio (Mean) | |||
|---|---|---|---|---|
| Baseline Right RAR | Baseline Left RAR | 12 months Right RAR | 12 months Left RAR | |
| Renal Denervation Group | 1.38 | 1.52 | 1.41 | 1.52 |
Dimensions of renal artery, right and left (NCT01628198)
Timeframe: baseline and 12 months
| Intervention | mm (Mean) | |||
|---|---|---|---|---|
| Baseline R Kidney | Baseline L Kidney | 12 months R Kidney | 12 months L Kidney | |
| Renal Denervation Group | 11.43 | 11.68 | 11.26 | 11.39 |
Renal artery blood flow as measured by Resistive Index. RI = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity. the normal value is ~ 0.60, with 0.70 being around the upper limits of normal (NCT01628198)
Timeframe: Baseline and 12 months
| Intervention | index (Mean) | |||
|---|---|---|---|---|
| Baseline Right RI | Baseline Left RI | 12 months Right RI | 12 months Left RI | |
| Renal Denervation Group | 0.67 | 0.72 | 0.72 | 0.72 |
1 review available for debrisoquin and Disease Models, Animal
| Article | Year |
|---|---|
Sympathetic activation in chronic renal failure.
Topics: Animals; Cardiovascular Diseases; Catecholamines; Clonidine; Debrisoquin; Disease Models, Animal; Ef | 2009 |
Sympathetic activation in chronic renal failure.
Topics: Animals; Cardiovascular Diseases; Catecholamines; Clonidine; Debrisoquin; Disease Models, Animal; Ef | 2009 |
Sympathetic activation in chronic renal failure.
Topics: Animals; Cardiovascular Diseases; Catecholamines; Clonidine; Debrisoquin; Disease Models, Animal; Ef | 2009 |
Sympathetic activation in chronic renal failure.
Topics: Animals; Cardiovascular Diseases; Catecholamines; Clonidine; Debrisoquin; Disease Models, Animal; Ef | 2009 |
3 other studies available for debrisoquin and Disease Models, Animal
| Article | Year |
|---|---|
Human hepatic stem cells transplanted into a fulminant hepatic failure Alb-TRECK/SCID mouse model exhibit liver reconstitution and drug metabolism capabilities.
Topics: Animals; Cell Differentiation; Cell Proliferation; Cells, Cultured; Chimera; Debrisoquin; Diphtheria | 2015 |
Debrisoquine 4-hydroxylation and the Balkan endemic nephropathy.
Topics: Animals; Balkan Nephropathy; Crosses, Genetic; Debrisoquin; Diet; Disease Models, Animal; Female; Fo | 1999 |
Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ) a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizer.
Topics: Animals; Brain; Chemical Phenomena; Chemistry; Debrisoquin; Disease Models, Animal; Female; Gas Chro | 1990 |